Compare CAPL & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | CERT |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.5M | 860.9M |
| IPO Year | 2012 | 2020 |
| Metric | CAPL | CERT |
|---|---|---|
| Price | $22.96 | $4.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 44.0K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | 87.50 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,869,806,000.00 | $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | $2.80 | $5.39 |
| P/E Ratio | $88.42 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $19.61 | $4.59 |
| 52 Week High | $23.24 | $13.88 |
| Indicator | CAPL | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 23.11 |
| Support Level | $20.06 | N/A |
| Resistance Level | N/A | $6.47 |
| Average True Range (ATR) | 0.56 | 0.34 |
| MACD | 0.22 | -0.18 |
| Stochastic Oscillator | 95.80 | 0.00 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.